ArticlePLoS neglected tropical diseases2025
Prevalence of antibodies against dengue virus in the city of Buenos Aires: Results of a probabilistic population survey.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Engineered Nanobodies for early and accurate diagnosis of dengue virus infection.PLoS neglected tropical diseases · 2025Article
- Dengue Outbreaks and Antibody Seroprevalence in Buenos Aires.The American journal of tropical medicine and hygiene · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveDengue is a rapidly growing global health issue. In Argentina, the disease burden is primarily based on case reports or retrospective series; however, there are no prospective probabilistic studies available. To estimate the seroprevalence of antibodies against the dengue virus (DENV) in adult residents of Buenos Aires, at the end of the 2023 season, which culminated in Argentina's largest recorded dengue outbreak, and immediately before the subsequent outbreak at the beginning of 2024.
methodsA stratified, multi-stage probabilistic population survey was conducted to ensure representativeness of the adult population of Buenos Aires, considering geographical and socio-economic diversity.The survey determined the seroprevalence rate of DENV IgG and IgM antibodies using a rapid chromatographic immunoassay. Antibody positive participants were invited for re-testing to confirm antibody result using an enzyme-linked fluorescence assay (ELFA) technique.
resultsOut of a sampling frame of 2,998 selected households, the interviewers visited 100% of the residences. The overall response rate was 26.8%. A total of 804 participants were enrolled, representing the city's 2.38 million adult population. Weighted estimates showed a total of 193,707 people aged 18 and over have antibodies to DENV. This implies a weighted prevalence [95% CI] of 8.12% [8.08%-8.15%]. The prevalence varied across different areas of the city. In the slums, the overall prevalence was twice as high (14.7% [14.5%-14.9%]) compared to the rest of the city (7.67% [7.63%-7.70%]).
conclusionSeroprevalence results in adults in Buenos Aires show a moderate DENV infection rate, although still far from the thresholds usually considered for initiating a mass vaccination campaign. These results underscore the need for frequent surveys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.